Extracellular matrix synthesis in vascular disease: Hypertension, and atherosclerosis

Journal of Biomedical Research

Volumn 28, Issue 1, 2014, Pages 25-39

  Ponticos, Markella ^a   Smith, Barbara D ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Extracellular matrix; Vascular disease

Indexed keywords

EID: 84899920099     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.27.20130064     Document Type: Article

References (164)

1. Wagenseil JE, Mecham RP. Elastin in large artery stiff-ness and hypertension. J Cardiovasc Transl Res 2012; 5: 264-73.
2. Cheng JK, Wagenseil JE. Extracellular matrix and the mechanics of large artery development. Biomech Model Mechanobiol 2012; 11: 1169-86.
3. Wagenseil JE, Mecham RP. Vascular extracellular matrix and arterial mechanics. Physiol Rev 2009; 89: 957-89.
4. Davis EC. Smooth muscle cell to elastic lamina connec-tions in developing mouse aorta. Role in aortic medial organization. Lab Invest 1993; 68: 89-99.
5. Davis EC. Endothelial cell connecting filaments anchor endothelial cells to the subjacent elastic lamina in the developing aortic intima of the mouse. Cell Tissue Res 1993; 272: 211-9.
6. Damiano V, Tsang A, Weinbaum G, Christner P, Rosen-bloom J. Secretion of elastin in the embryonic chick aorta as visualized by immunoelectron microscopy. Coll Relat Res 1984; 4: 153-64.
7. Mecham RP, Madaras J, McDonald JA, Ryan U. Elastin production by cultured calf pulmonary artery endothelial cells. J Cell Physiol 1983; 116: 282-8.
8. Berry CL, Sosa-Melgarejo JA, Greenwald SE. The rela-tionship between wall tension, lamellar thickness, and intercellular junctions in the fetal and adult aorta: its rel-evance to the pathology of dissecting aneurysm. J Pathol 1993; 169: 15-20.
9. Rhodin JA. Ultrastructure of mammalian venous capil-laries, venules, and small collecting veins. J Ultrastruct Res 1968; 25: 452-500.
10. Majesky MW. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol 2007; 27: 1248-58.
11. Domigan CK, Iruela-Arispe ML. Recent advances in vas-cular development. Curr Opin Hematol 2012; 19: 176-83.
12. Goddard LM, Iruela-Arispe ML. Cellular and molecular regulation of vascular permeability. Thromb Haemost 2013; 109.
13. Arroyo AG, Iruela-Arispe ML. Extracellular matrix, in-flammation, and the angiogenic response. Cardiovasc Res 2010; 86: 226-35.
14. Wang M, Monticone RE, Lakatta EG. Arterial aging: a journey into subclinical arterial disease. Curr Opin Ne-phrol Hypertens 2010; 19: 201-7.
15. Erusalimsky JD, Skene C. Mechanisms of endothelial senescence. Exp Physiol 2009; 94: 299-304.
16. Erusalimsky JD. Vascular endothelial senescence: from mechanisms to pathophysiology. J Appl Physiol 2009; 106: 326-32.
17. Topouzis S, Majesky MW. Smooth muscle lineage di-versity in the chick embryo. Two types of aortic smooth muscle cell differ in growth and receptor-mediated tran-scriptional responses to transforming growth factor-beta. Dev Biol 1996; 178: 430-45.
18. Larsson E, McLean SE, Mecham RP, Lindahl P, Neland-er S. Do two mutually exclusive gene modules define the phenotypic diversity of mammalian smooth muscle? Mol Genet Genomics 2008; 280: 127-37.
19. Chamley-Campbell J, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev 1979; 59: 1-61.
20. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res 2012; 95: 156-64.
21. Owens GK, Kumar MS, Wamhoff BR. Molecular regu-lation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004; 84: 767-801.
22. Gabbiani G, Badonnel MC. Contractile events during in-flammation. Agents Actions 1976; 6(1-3): 277-80.
23. Gabbiani G. The myofibroblast: a key cell for wound healing and fibrocontractive diseases. Prog Clin Biol Res 1981; 54: 183-94.
24. Majesky MW, Dong XR, Hoglund V, Daum G, Mahoney WM Jr. The adventitia: a progenitor cell niche for the vessel wall. Cells Tissues Organs 2012; 195(1-2): 73-81.
25. Sartore S, Chiavegato A, Faggin E, Franch R, Puato M, Ausoni S, et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res 2001; 89: 1111-21.
26. Scott NA, Cipolla GD, Ross CE, Dunn B, Martin FH, Simonet L, et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circula-tion 1996; 93: 2178-87.
27. Majesky MW, Dong XR, Regan JN, Hoglund VJ. Vas-cular smooth muscle progenitor cells: building and re-pairing blood vessels. Circ Res 2011; 108: 365-77.
28. Majesky MW, Dong XR, Hoglund V, Mahoney WM Jr, Daum G. The adventitia: a dynamic interface containing resident progenitor cells. Arterioscler Thromb Vasc Biol 2011; 31: 1530-9.
29. Sato Y, Poynter G, Huss D, Filla MB, Czirok A, Rong-ish BJ, et al. Dynamic analysis of vascular morphogen-esis using transgenic quail embryos. PLoS One 2010; 5: e12674.
30. Forsten-Williams K, Kurtagic E, Nugent MA. Complex receptor-ligand dynamics control the response of the VEGF system to protease injury. BMC systems biology 2011; 5: 170.
31. Symes K, Smith EM, Mitsi M, Nugent MA. Sweet cues: How heparan sulfate modification of fibronectin enables growth factor guided migration of embryonic cells. Cell Adh Migr 2010; 4: 507-10.
32. Hirschi KK, D'Amore PA. Pericytes in the microvascu-lature. Cardiovasc Res 1996; 32: 687-98.
33. Kielty CM, Sherratt MJ, Shuttleworth CA. Elastic fibres. J Cell Sci 2002; 115(Pt 14): 2817-28.
34. Kielty CM, Baldock C, Lee D, Rock MJ, Ashworth JL, Shuttleworth CA. Fibrillin: from microfibril assembly to biomechanical function. Philos Trans R Soc Lond B Biol Sci 2002; 357: 207-17.
35. Ramirez F, Pereira L. The fibrillins. Int J Biochem Cell Biol 1999; 31: 255-9.
36. Arteaga-Solis E, Gayraud B, Ramirez F. Elastic and collagenous networks in vascular diseases. Cell Struct Funct 2000; 25: 69-72.
37. Kielty CM, Wess TJ, Haston L, Ashworth JL, Sherratt MJ, Shuttleworth CA. Fibrillin-rich microfibrils: elastic biopolymers of the extracellular matrix. J Muscle Res Cell Motil 2002; 23(5-6): 581-96.
38. Ramirez F, Sakai LY. Biogenesis and function of fibril-lin assemblies. Cell Tissue Res 2010; 339: 71-82.
39. Nistala H, Lee-Arteaga S, Smaldone S, Siciliano G, Carta L, Ono RN, et al. Fibrillin-1 and -2 differentially modu-late endogenous TGF-beta and BMP bioavailability dur-ing bone formation. J Cell Biol 2010; 190: 1107-21.
40. Bax DV, Mahalingam Y, Cain S, Mellody K, Freeman L, Younger K, et al. Cell adhesion to fibrillin-1: identifica-tion of an Arg-Gly-Asp-dependent synergy region and a heparin-binding site that regulates focal adhesion forma-tion. J Cell Sci 2007; 120(Pt 8): 1383-92.
41. Morris CA. Genetic aspects of supravalvular aortic ste-nosis. Current opinion in cardiology 1998; 13: 214-9.
42. Curran ME, Atkinson DL, Ewart AK, Morris CA, Lep-pert MF, Keating MT. The elastin gene is disrupted by a translocation associated with supravalvular aortic steno-sis. Cell 1993; 73: 159-68.
43. Li DY, Faury G, Taylor DG, et al. Novel arterial pathol-ogy in mice and humans hemizygous for elastin. J Clin Invest 1998;102:1783-7.
44. Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, et al. Elastin is an essential determinant of arterial mor-phogenesis. Nature 1998; 393: 276-80.
45. Hocking AM, Shinomura T, McQuillan DJ. Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol 1998; 17: 1-19.
46. Alexopoulou AN, Multhaupt HA, Couchman JR. Synde-cans in wound healing, inflammation and vascular biol-ogy. Int J Biochem Cell Biol 2007; 39: 505-28.
47. Dingemans KP, Teeling P, Lagendijk JH, Becker AE. Extracellular matrix of the human aortic media: an ul-trastructural histochemical and immunohistochemical study of the adult aortic media. Anat Rec 2000; 258: 1-14.
48. Reinecke H, Robey TE, Mignone JL, Muskheli V, Born-stein P, Murry CE. Lack of thrombospondin-2 reduces fibrosis and increases vascularity around cardiac cell grafts. Cardiovasc Pathol 2013; 22: 91-5.
49. Budhani F, Leonard KA, Bergdahl A, Gao J, Lawler J, Davis EC. Vascular response to intra-arterial injury in the thrombospondin-1 null mouse. J Mol Cell Cardiol 2007; 43: 210-4.
50. Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, et al. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol 1998; 140: 419-30.
51. Rivera LB, Bradshaw AD, Brekken RA. The regulatory function of SPARC in vascular biology. Cell Mol Life Sci 2011; 68: 3165-73.
52. Wang L, Wang W, Shah PK, Song L, Yang M, Sharifi BG. Deletion of tenascin-C gene exacerbates athero-sclerosis and induces intraplaque hemorrhage in Apo-E-deficient mice. Cardiovasc Pathol 2012; 21: 398-413.
53. Layne MD, Yet SF, Maemura K, Hsieh CM, Liu X, Ith B, et al. Characterization of the mouse aortic carboxypepti-dase-like protein promoter reveals activity in differenti-ated and dedifferentiated vascular smooth muscle cells. Circ Res 2002; 90: 728-36.
54. Layne MD, Endege WO, Jain MK, et al. Aortic carbox-ypeptidase-like protein, a novel protein with discoidin and carboxypeptidase-like domains, is up-regulated dur-ing vascular smooth muscle cell differentiation. J Biol Chem 1998; 273: 15654-160.
55. Ponticos M. Connective Tissue Growth Factor (CCN2) in Blood Vessels. Vascul Pharmacol 2013; 58: 189-93.
56. Murphy G, Nagase H. Progress in matrix metalloprotein-ase research. Mol Aspects Med 2008; 29: 290-308.
57. Myllyharju J, Kivirikko KI. Collagens, modifying en-zymes and their mutations in humans, flies and worms. Trends Genet 2004; 20: 33-43.
58. Kelleher CM, McLean SE, Mecham RP. Vascular ex-tracellular matrix and aortic development. Curr Top Dev Biol 2004; 62: 153-88.
59. Wenstrup RJ, Florer JB, Brunskill EW, Bell SM, Ch-ervoneva I, Birk DE. Type V collagen controls the ini-tiation of collagen fibril assembly. J Biol Chem 2004; 279: 53331-7.
60. Wenstrup RJ, Florer JB, Davidson JM, Phillips CL, Pfeiffer BJ, Menezes DW, et al. Murine model of the Ehlers-Danlos syndrome. col5a1 haploinsufficiency dis-rupts collagen fibril assembly at multiple stages. J Biol Chem 2006; 281: 12888-95.
61. Sawabe M. Vascular aging: from molecular mechanism to clinical significance. Geriatr Gerontol Int 2010; 10 (S1): 213-20
62. Halka AT, Turner NJ, Carter A, Ghosh J, Murphy MO, Kirton JP,et al. The effects of stretch on vascu-lar smooth muscle cell phenotype in vitro. Cardiovasc Pathol 2008; 17: 98-102.
63. Gieni RS, Hendzel MJ. Mechanotransduction from the ECM to the genome: are the pieces now in place? J Cell Biochem 2008; 104: 1964-87.
64. Ingber DE. Tensegrity II. How structural networks influ-ence cellular information processing networks. J Cell Sci 2003; 116(Pt 8): 1397-408.
65. Ingber DE. The architecture of life. Sci Am 1998; 278: 48-57.
66. Ingber DE, Dike L, Hansen L, Karp S, Liley H, Maniotis A, et al. Cellular tensegrity: exploring how mechanical changes in the cytoskeleton regulate cell growth, migra-tion, and tissue pattern during morphogenesis. Int Rev Cytol 1994; 150: 173-224.
67. Lim SM, Trzeciakowski JP, Sreenivasappa H, Dangott LJ, Trache A. RhoA-induced cytoskeletal tension con-trols adaptive cellular remodeling to mechanical signal-ing. Integr Biol (Camb) 2012; 4: 615-27.
68. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, et al. Role of YAP/TAZ in mechan-otransduction. Nature 2011; 474: 179-83.
69. Chen J, Kitchen CM, Streb JW, Miano JM. Myocardin: a component of a molecular switch for smooth muscle differentiation. J Mol Cell Cardiol 2002; 34: 1345-56.
70. Manabe I, Owens GK. CArG elements control smooth muscle subtype-specific expression of smooth muscle myosin in vivo. J Clin Invest 2001; 107: 823-34.
71. Mack CP, Somlyo AV, Hautmann M, Somlyo AP, Owens GK. Smooth muscle differentiation marker gene expres-sion is regulated by RhoA-mediated actin polymerization. J Biol Chem 2001; 276: 341-7.
72. Kawai-Kowase K, Owens GK. Multiple repressor path-ways contribute to phenotypic switching of vascular smooth muscle cells. Am J Physiol Cell Physiol 2007; 292: C59-69
73. Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol 2010; 11: 353-65
74. Parmacek MS. Myocardin-related transcription factors: critical coactivators regulating cardiovascular develop-ment and adaptation. Circ Res 2007; 100: 633-44
75. Pipes GC, Creemers EE, Olson EN. The myocardin fam-ily of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis. Genes Dev 15 2006; 20: 1545-56.
76. Imamura M, Long X, Nanda V, Miano JM. Expression and functional activity of four myocardin isoforms. Gene 2010; 464(1-2): 1-10.
77. Sun Q, Taurin S, Sethakorn N, Long X, Imamura M, Wang DZ, et al. Myocardin-dependent activation of the CArG box-rich smooth muscle gamma-actin gene: preferential utilization of a single CArG element through functional association with the NKX3.1 homeodomain protein. J Biol Chem 2009; 284: 32582-90.
78. Long X, Bell RD, Gerthoffer WT, Zlokovic BV, Miano JM. Myocardin is sufficient for a smooth muscle-like contractile phenotype. Arterioscler Thromb Vasc Biol 2008; 28: 1505-10.
79. Du KL, Ip HS, Li J, Chen M, Dandre F, Yu W, et al. Myocardin is a critical serum response factor cofactor in the transcriptional program regulating smooth muscle cell differentiation. Mol Cell Biol 2003; 23: 2425-37.
80. Asparuhova MB, Gelman L, Chiquet M. Role of the ac-tin cytoskeleton in tuning cellular responses to external mechanical stress. Scand J Med Sci Sports 2009; 19: 490-9.
81. Wei K, Che N, Chen F. Myocardin-related transcription factor B is required for normal mouse vascular devel-opment and smooth muscle gene expression. Dev Dyn 2007; 236: 416-25.
82. Sun Y, Boyd K, Xu W, Ma J, Jackson CW, Fu A, et al. Acute myeloid leukemia-associated Mkl1 (Mrtf-a) is a key regulator of mammary gland function. Mol Cell Biol 2006; 26: 5809-26.
83. Li S, Chang S, Qi X, Richardson JA, Olson EN. Re-quirement of a myocardin-related transcription factor for development of mammary myoepithelial cells. Mol Cell Biol 2006; 26: 5797-808.
84. Minami T, Kuwahara K, Nakagawa Y, Takaoka M, Kinoshita H, Nakao K, et al. Reciprocal expression of MRTF-A and myocardin is crucial for pathological vas-cular remodelling in mice. EMBO J 2012; 31: 4428-40.
85. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, Plato CF, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009; 23: 2166-78.
86. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009; 460: 705-10.
87. Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal le-sion formation. Circ Res 2009; 105: 158-166.
88. Jiang Y, Yin H, Zheng XL. MicroRNA-1 inhibits myo-cardin-induced contractility of human vascular smooth muscle cells. J Cell Physiol 2010; 225: 506-11.
89. Zhang X, Azhar G, Helms SA, Wei JY. Regulation of cardiac microRNAs by serum response factor. J Biomed Sci 2011; 18: 15.
90. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of mi-croRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008; 105: 13027-32.
91. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 2012; 44: 237-44.
92. Hubmacher D, Apte SS. The biology of the extracellular matrix: novel insights. Curr Opin Rheumatol 2013; 25: 37 65-70.
93. He Y, Huang C, Lin X, Li J. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie 2013; 95: 1355-9.
94. Xiao J, Meng XM, Huang XR, Chung AC, Feng YL, Hui DS, et al. miR-29 Inhibits Bleomycin-induced Pulmo-nary Fibrosis in Mice. Mol Ther 2012; 20: 1251-60.
95. Roderburg C, Urban GW, Bettermann K, Vucur M, Zim-mermann H, Schmidt S, et al. Micro-RNA profiling re-veals a role for miR-29 in human and murine liver fibro-sis. Hepatology 2011; 53: 209-18.
96. Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol 2011; 45: 287-94.
97. Maurer B, Stanczyk J, Jünngel A, Akhmetshina A, Trenk-mann M, Brock M,et al. miR-29 is a key regulator of col-lagen expression in systemic sclerosis. Arthritis Rheum 2010; 62: 1733-43.
98. Crider BJ, Risinger GM Jr, Haaksma CJ, Howard EW, Tomasek JJ. Myocardin-related transcription factors A and B are key regulators of TGF-beta1-induced fibrob-last to myofibroblast differentiation. J Invest Dermatol 2011; 131: 2378-85.
99. Huang X, Yang N, Fiore VF, Barker TH, Sun Y, Morris SW, et al. Matrix Stiffness-Induced Myofibroblast Dif-ferentiation Is Mediated by Intrinsic Mechanotransduc-tion. Am J Respir Cell Mol Biol 2012; 47: 340-8.
100. Tomasek JJ, Vaughan MB, Kropp BP, Gabbiani G, Martin MD, Haaksma CJ, et al. Contraction of myofi-broblasts in granulation tissue is dependent on Rho/Rho kinase/myosin light chain phosphatase activity. Wound Repair Regen 2006; 14: 313-20.
101. Wipff PJ, Hinz B. Myofibroblasts work best under stress. J Bodyw Mov Ther 2009; 13: 121-7.
102. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoul-iere A, Varga J, et al. Recent developments in myofi-broblast biology: paradigms for connective tissue re-modeling. Am J Pathol 2012; 180: 1340-55.
103. Klingberg F, Hinz B, White ES. The myofibroblast ma-trix: implications for tissue repair and fibrosis. J Pathol 2013; 229: 298-309.
104. Intengan HD, Schiffrin EL. Vascular remodeling in hy-pertension: roles of apoptosis, inflammation, and fibro-sis. Hypertension 2001; 38(3 Pt 2): 581-7.
105. Osherov AB, Gotha L, Cheema AN, Qiang B, Strauss BH. Proteins mediating collagen biosynthesis and ac-cumulation in arterial repair: novel targets for anti-restenosis therapy. Cardiovasc Res 2011; 91: 16-26.
106. Lan TH, Huang XQ, Tan HM. Vascular fibrosis in atherosclerosis. Cardiovasc Pathol 2013 doi: 10.1016/ j.carpath.2013.01.003.
107. Ohtani N, Hara E. Roles and mechanisms of cellular se-nescence in regulation of tissue homeostasis. Cancer Sci 2013; 104: 525-30.
108. Campisi J, Andersen JK, Kapahi P, Melov S. Cellular senescence: a link between cancer and age-related de-generative disease? Semin Cancer Biol 2011; 21: 354-9.
109. Burton DG, Matsubara H, Ikeda K. Pathophysiology of vascular calcification: Pivotal role of cellular senescence in vascular smooth muscle cells. Exp Gerontol 2010; 45: 819-24.
110. Liu Y, Drozdov I, Shroff R, Beltran LE, Shanahan CM. Prelamin a accelerates vascular calcification via activa-tion of the DNA damage response and senescence-as-sociated secretory phenotype in vascular smooth muscle cells. Circ Res 2013; 112: e99-e109.
111. Ho CY, Jaalouk DE, Vartiainen MK, Lammerding J. Lamin A/C and emerin regulate MKL1-SRF activity by modulating actin dynamics. Nature. May 5 2013.
112. Luchsinger LL, Patenaude CA, Smith BD, Layne MD. Myocardin-related Transcription Factor-A Complexes Activate Type I Collagen Expression in Lung Fibrob-lasts. J Biol Chem 2011; 286: 44116-25.
113. Siefert SA, Sarkar R. Matrix metalloproteinases in vas-cular physiology and disease. Vascular 2012; 20(4): 210-6.
114. Fleming TH, Humpert PM, Nawroth PP, Bierhaus A. Reactive metabolites and AGE/RAGE-mediated cellu-lar dysfunction affect the aging process: a mini-review. Gerontology 2011; 57: 435-43.
115. Franklin SS. Arterial stiffness and hypertension: a two-way street? Hypertension 2005; 45: 349-51.
116. Dernellis J, Panaretou M. Aortic stiffness is an independ-ent predictor of progression to hypertension in nonhy-pertensive subjects. Hypertension 2005; 45: 426-31.
117. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical clas-sification of pulmonary hypertension. J Am Coll Cardiol 2009; 54(1 S): 43-54.
118. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008; 118: 2372-9.
119. Rabinovitch M. Pathobiology of pulmonary hyperten-sion. Annu Rev Pathol 2007; 2: 369-99.
120. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exu-berant endothelial cell growth and elements of inflam-mation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144: 275-85.
121. Weber C, Zernecke A, Libby P. The multifaceted con-tributions of leukocyte subsets to atherosclerosis: les-sons from mouse models. Nat Rev Immunol 2008; 8: 802-15.
122. Libby P. Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol 2006; 98(12A): 3Q-9Q.
123. Rekhter MD. Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc Res 1999; 41: 376-84.
124. Geary RL, Wong JM, Rossini A, Schwartz SM, Adams LD. Expression profiling identifies 147 genes contribut-ing to a unique primate neointimal smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 2002; 22: 2010-6.
125. Libby P. Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. J Lipid Resr 2009; 50 (S): 352-7.
126. Rekhter M. Vulnerable atherosclerotic plaque: emerging challenge for animal models. Curr Opin Cardiol 2002; 17: 626-32.
127. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehen-sive morphological classification scheme for atheroscle-rotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-75.
128. Newby AC. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2008; 28: 2108-14.
129. Abraham D, Ponticos M, Nagase H. Connective tissue remodeling: cross-talk between endothelins and matrix metalloproteinases. Curr Vasc Pharmacol 2005; 3: 369-79.
130. Jawien J, Nastalek P, Korbut R. Mouse models of ex-perimental atherosclerosis. J Physiol Pharmacol 2004; 55: 503-17.
131. Roque M, Fallon JT, Badimon JJ, Zhang WX, Taubman MB, Reis ED. Mouse model of femoral artery denuda-tion injury associated with the rapid accumulation of ad-hesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol 2000; 20: 335-42.
132. Zhu C, Wang Y, Kuai W, Sun X, Chen H, Hong Z. prognostic value of miR-29a expression in pediatric acute myeloid leukemia. Clin Biochem 2013; 46(1-2): 49-53.
133. Bou-Gharios G, Ponticos M, Rajkumar V, Abraham D. Extra-cellular matrix in vascular networks. Cell Prolif 2004; 37: 207-20.
134. Bedalov A, Breault DT, Sokolov BP, Lichtler AC, Bedalov I, Clark SH, et al. Regulation of the alpha 1(I) collagen promoter in vascular smooth muscle cells. Comparison with other alpha 1(I) collagen-producing cells in transgenic animals and cultured cells. J Biol Chem 1994; 269: 4903-9.
135. Niederreither K, D'Souza RN, de Crombrugghe B. Mini-mal DNA sequences that control the cell lineage-specific expression of the pro alpha 2(I) collagen promoter in transgenic mice. J Cell Biol 1992; 119: 1361-70.
136. Bou-Gharios G, Garrett LA, Rossert J, et al. A potent far-upstream enhancer in the mouse pro alpha 2(I) collagen gene regulates expression of reporter genes in transgenic mice. J Cell Biol 1996; 134: 1333-44.
137. Ramirez F, Tanaka S, Bou-Gharios G. Transcriptional regulation of the human alpha2(I) collagen gene (CO-L1A2), an informative model system to study fibrotic diseases. Matrix Biol 2006; 25: 365-72.
138. Sengupta PK, Erhlich M, Smith BD. A methylation-responsive MDBP/RFX site is in the first exon of the collagen alpha 2(I) promoter. J Biol Chem 1999; 274: 36649-55.
139. Sengupta PK, Smith BD. Methylation in the initiation region of the first exon suppresses collagen pro-alpha2(I) gene transcription. Biochim Biophys Acta 1998; 1443(1-2): 75-89.
140. Sengupta S, Smith EM, Kim K, Murnane MJ, Smith BD. DNA hypermethylation near the transcription start site of collagen alpha2(I) gene (COL1A2) occurs in both cancer cell lines and primary colorectal cancers. Cancer Res 2003; 63: 1789-97.
141. Sengupta PK, Fargo J, Smith BD. The RFX family in-teracts at the collagen (COL1A2) start site and represses transcription. J Biol Chem 2002; 277: 24926-37.
142. Xu Y, Wang L, Buttice G, Sengupta PK, Smith BD. In-terferon gamma repression of collagen (COL1A2) tran-scription is mediated by the RFX5 complex. J Biol Chem 2003; 278: 49134-44.
143. Xu Y, Wang L, Buttice G, Sengupta PK, Smith BD. Ma-jor Histocompatibility Class II Transactivator (CIITA) Mediates Repression of Collagen (COL1A2) Transcrip-tion by Interferon gamma (IFN-gamma). J Biol Chem 2004; 279: 41319-32.
144. Sengupta P, Xu Y, Wang L, Widom R, Smith BD. Col-lagen alpha1(I) Gene (COL1A1) is Repressed by RFX Family. J Biol Chem 2005; 280: 21004-14.
145. Xu Y, Sengupta PK, Seto E, Smith BD. RFX family proteins differentially interact with HDACs to repress collagen alpha 2(I) gene (COL1A2) expression. J Biol Chem 2006; 281: 9260-70.
146. Xu Y, Harton JA, Smith BD. CIITA mediates interferon-gamma repression of collagen transcription through phosphorylation-dependent interactions with co-repres-sor molecules. J Biol Chem 2008; 283: 1243-56.
147. Wu X, Kong X, Luchsinger L, Smith BD, Xu Y. Regu-lating the activity of class II transactivator by posttrans-lational modifications: exploring the possibilities. Mol Cell Biol 2009; 29: 5639-44.
148. Xu Y, Farmer SR, Smith BD. Peroxisome proliferator-activated receptor gamma interacts with CIITA/RFX5 complex to repress type I collagen gene expression. J Biol Chem 2007; 282: 26046-56.
149. Xu Y, Ravid K, Smith BD. Major histocompatibility class II transactivator (CIITA) expression in smooth muscle cells from A2b adenosine receptor knockout mice: crosstalk between the adenosine and IFN-gamma signaling. J Biol Chem 2008; 283: 14213-20.
150. Nehls MC, Brenner DA, Gruss HJ, Dierbach H, Mertels-mann R, Herrmann F. Mithramycin selectively inhibits collagen-alpha 1(I) gene expression in human fibroblast. J Clin Invest 1993; 92: 2916-21.
151. Tamaki T, Ohnishi K, Hartl C, LeRoy EC, Trojanowska M. Characterization of a GC-rich region containing Sp1 binding site(s) as a constitutive responsive element of the alpha 2(I) collagen gene in human fibroblasts. J Biol Chem 1995; 270: 4299-304.
152. Czuwara-Ladykowska J, Sementchenko VI, Watson DK, Trojanowska M. Ets1 is an effector of the transforming growth factor beta (TGF-beta ) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. J Biol Chem 2002; 277: 20399-408.
153. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001; 276: 20839-48.
154. Greenwel P, Inagaki Y, Hu W, Walsh M, Ramirez F. Sp1 is required for the early response of alpha2(I) collagen to transforming growth factor-beta1. J Biol Chem 1997; 272: 19738-45.
155. Greenwel P, Tanaka S, Penkov D, Zhang W, Olive M, Moll J, et al. Tumor necrosis factor alpha inhibits type I collagen synthesis through repressive CCAAT/enhancer-binding proteins. Mol Cell Biol 2000; 20: 912-8.
156. Small EM, Thatcher JE, Sutherland LB, Kinoshita H, Gerard RD, Richardson JA, et al. Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res 2010; 107: 294-304.
157. Hendrix JA, Wamhoff BR, McDonald OG, Sinha S, Yoshida T, Owens GK. 5' CArG degeneracy in smooth muscle alpha-actin is required for injury-induced gene suppression in vivo. J Clin Invest 2005; 115: 418-27.
158. Deaton RA, Gan Q, Owens GK. Sp1-dependent activa-tion of KLF4 is required for PDGF-BB-induced pheno-typic modulation of smooth muscle. Am J Physiol Heart Circ Physiol 2009; 296: H1027-37.
159. Antoniv TT, De Val S, Wells D, Denton CP, Rabe C, de Crombrugghe B, et al. Characterization of an evolu-tionarily conserved far-upstream enhancer in the human alpha 2(I) collagen (COL1A2) gene. J Biol Chem 2001; 276: 21754-64.
160. De Val S, Ponticos M, Antoniv TT, Wells DJ, Abraham D, Partridge T, et al. Identification of the key regions within the mouse pro-alpha 2(I) collagen gene far-up-stream enhancer. J Biol Chem 2002; 277: 9286-92.
161. Ponticos M, Abraham D, Alexakis C, Lu QL, Black C, Partridge T, et al. Col1a2 enhancer regulates collagen activity during development and in adult tissue repair. Matrix Biol 2004; 22:619-28.
162. Inagaki Y, Truter S, Bou-Gharios G, Garrett LA, de Crombrugghe B, Nemoto T, et al. Activation of Proalpha2(I) collagen promoter during hepatic fibrogen-esis in transgenic mice. Biochem Biophys Res Commun 1998; 250: 606-11.
163. Denton CP, Zheng B, Shiwen X, et al. Activation of a fibroblast-specific enhancer of the proalpha2(I) collagen gene in tight-skin mice. Arthritis Rheum 2001; 44: 712-22.
164. Rajkumar VS, Shiwen X, Bostrom M, Leoni P, Muddle J, Ivarsson M, et al. Platelet-derived growth factor-beta receptor activation is essential for fibroblast and peri-cyte recruitment during cutaneous wound healing. Am J Pathol 2006; 169: 2254-65.